StocksMedium•10 November 2026•
1 min read
Prime Medicine Launches $125 Million Public Offering for Genetic Therapy Development
Key Facts
1Prime Medicine announced the commencement of an underwritten public offering of $125 million of its common stock.
2The company intends to grant underwriters a 30-day option to purchase up to an additional $18.75 million of shares.
Prime Medicine announced the commencement of an underwritten public offering of $125 million of its common stock. According to GlobeNewswire, the company intends to grant underwriters a 30-day option to purchase up to an additional $18.75 million of shares. The offering is designed to raise capital for the biotechnology firm's operations and the development of genetic therapies.
PRME closed at $4.3 on November 9, 2026, with the stock trading between a day low of $4.22 and a high of $4.71. This capital raise is directed toward funding the company's specialized research within the biotech sector, even as such public offerings typically introduce potential short-term dilution for existing shareholders.